These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 8482334)
41. Transformation suppressor activity of C3G is independent of its CDC25-homology domain. Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107 [TBL] [Abstract][Full Text] [Related]
43. Reversion and rereversion in ras-transformed cells. Marshall CJ Immunol Ser; 1990; 51():89-106. PubMed ID: 2128917 [No Abstract] [Full Text] [Related]
44. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379 [TBL] [Abstract][Full Text] [Related]
45. Tumor-suppressive function of mutated gelsolin in ras-transformed cells. Müllauer L; Fujita H; Ishizaki A; Kuzumaki N Oncogene; 1993 Sep; 8(9):2531-6. PubMed ID: 8395682 [TBL] [Abstract][Full Text] [Related]
47. A role for Ras in v-Crk transformation. Greulich H; Hanafusa H Cell Growth Differ; 1996 Nov; 7(11):1443-51. PubMed ID: 8930393 [TBL] [Abstract][Full Text] [Related]
48. Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line. Zongaro S; de Stanchina E; Colombo T; D'Incalci M; Giulotto E; Mondello C Cancer Res; 2005 Dec; 65(24):11411-8. PubMed ID: 16357149 [TBL] [Abstract][Full Text] [Related]
49. Oncogene-mediated multistep transformation of C3H10T1/2 cells. Taparowsky EJ; Heaney ML; Parsons JT Cancer Res; 1987 Aug; 47(15):4125-9. PubMed ID: 3300959 [TBL] [Abstract][Full Text] [Related]
50. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812 [TBL] [Abstract][Full Text] [Related]
51. NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Jo H; Zhang R; Zhang H; McKinsey TA; Shao J; Beauchamp RD; Ballard DW; Liang P Oncogene; 2000 Feb; 19(7):841-9. PubMed ID: 10702792 [TBL] [Abstract][Full Text] [Related]
52. Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Sklar MD Cancer Res; 1988 Feb; 48(4):793-7. PubMed ID: 3276398 [TBL] [Abstract][Full Text] [Related]
53. Selective lack of intercellular communication between transformed and nontransformed cells as a common property of chemical and oncogene transformation of BALB/c 3T3 cells. Yamasaki H; Hollstein M; Mesnil M; Martel N; Aguelon AM Cancer Res; 1987 Nov; 47(21):5658-64. PubMed ID: 3311356 [TBL] [Abstract][Full Text] [Related]
54. R-Ras promotes tumor growth of cervical epithelial cells. Rincón-Arano H; Rosales R; Mora N; Rodriguez-Castañeda A; Rosales C Cancer; 2003 Feb; 97(3):575-85. PubMed ID: 12548599 [TBL] [Abstract][Full Text] [Related]
55. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells. Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316 [TBL] [Abstract][Full Text] [Related]
56. Analysis of the tumor suppressor activity of the K-rev-1 gene in human tumor cell lines. Sato KY; Polakis PG; Haubruck H; Fasching CL; McCormick F; Stanbridge EJ Cancer Res; 1994 Jan; 54(2):552-9. PubMed ID: 8275494 [TBL] [Abstract][Full Text] [Related]
57. Isolation of oncogenes from rat mammary tumors by a highly efficient retrovirus expression cloning system. Tsukamoto T; Huang T; Guzman RC; Chen X; Pascual RV; Kitamura T; Nandi S Biochem Biophys Res Commun; 1999 Nov; 265(1):7-12. PubMed ID: 10548482 [TBL] [Abstract][Full Text] [Related]